The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. by Hickish, T. et al.
Br. J. Cancer (1993), 68, 668-672 Macmillan Press Ltd., 1993~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The effect of 1,25-dihydroxyvitamin D, on lymphoma cell lines and
expression of vitamin D receptor in lymphoma
T. Hickishi, D. Cunningham', K. Colston4, B.C. Millar', J. Sandle2, A.G. Mackay4, M. Soukops
& J. Sloane3
'Lymphoma Unit and Section ofMedicine, 2Section ofImmunology and 3Department ofHistopathology, Institute ofCancer
Research, Royal Marsden Hospital, Sutton, Surrey SM2 SPT; 4Department ofClinical Biochemistry, St. Georges Hospital,
Medical School, London SW17; 'Department ofMedical Oncology, Glasgow Royal Infirmary, Glasgow G4 OSF, UK.
Summary 1,25(OH)2D3 promotes differentiation and has an antiproliferative effect in a variety of cell lines
derived from the immunohaematopoetic system. a-Calcidol which is metabolised to 1,25(OH)2D3 has been
shown to produce tumour regression in follicular low grade non-Hodgkin's lymphoma (NHL) and the dose
limiting toxicity is hypercalcaemia. The cellular action of 1,25(OH)2D3 is mediated by binding to an intracel-
lular protein, the vitamin D receptor (VDR). We have evaluated the activity of 1,25(OH)2D3 and its
non-calcaemogenic analogue MC903 in the SU-DHL4 and SU-DUL5 B cell lines which carry the 14;18
translocation characteristic of follicular NHL, and also the expression of the VDR in a range of B cell NHLs.
Both agents induced differentiation and had an antiproliferative effect on the SU-DHL4 and SU-DUL5 cell
lines. However this occurred at a relatively high concentration (10'- M) which exceeds the physiological
concentration of 1,25(OH)2D3 by approximately 103 104-fold. Expression of the VDR was low in each cell line
and in the low grade lymphoma tumour samples. To account for the observed clinical response to laOHD3
(a-calcidol) in follicular NHL a network is suggested whereby 1,25(OH)2D3 modulates the activity of CD4+T
cells which have previously been shown to promote follicle centre cell proliferation. Vitamin D3 analogues may
enable serum levels to be achieved which produce a direct action on follicular lymphoma cells without
disturbing calcium metabolism.
1,25(OH)2D3 is the active metabolite of vitamin D3 and its
action is mediated by an intracellular receptor (VDR) which
binds to DNA (Mangelsdorf et al., 1984; Reichel et al.,
1989). The presence of the VDR in cells of the immuno-
haemopoetic system first indicated 1,25(OH)2D3 may have a
role in regulating their activity. 1,25(OH)2D3 has been shown
in vitro to have an antiproliferative effect and promote
differentiation in monoblastic and promyelocytic cell lines, to
inhibit differentiation in K562 leukaemia cells, to inhibit IL-1
production, to suppress CD4+T cell proliferation and IL2
production and inhibit immunoglobulin production by B
cells (Jordan et al., 1990; Rebel et al., 1992; Tsoukas et al.,
1989; Rigby et al., 1987; Moore et al., 1991; Iho et al., 1986;
Tsoukas et al., 1984; Bhalla et al., 1989). In a number of cell
lines the degree of response to 1,25(OH)2D3 appears to be
dependent on the level of ligand binding (Chen et al., 1986)
however the precise relationship is unknown. Furthermore
1,25(OH)2D3 has been shown to modulate expression of its
own receptor (Lee et al., 1989; Strom et al., 1989). In actively
proliferating lymphocytes VDR expression appears to be
high and correlates with proliferative status except in B-cells
in which expression is low (Kizaki et al., 1991).
B cell lymphomas have been shown to be sensitive to
vitamin D3. In a clinical trial, 1 lsg of l1,25OHD3 (a-calcidol)
daily (metabolised to 1,25(OH)2D3 in the liver) produced an
overall response rate of 30% in advanced follicular B cell
non-Hodgkin's lymphoma (NHL) (Raina et al., 1991). The
clinical importance of this finding is that it indicates
vitamin D3 may have a role as a maintenance therapy in the
setting of minimal residual disease in follicular NHL.
Vitamin D3 analogues which have the antiproliferative effect
of 1,25(OH)2D3 but lack its effect on calcium metabolism
have been evaluated in a number of cell lines (Norman et al.,
1990; Zhou et al., 1989; Binderup & Bramm, 1988; Colston
et al., 1992). These could be of clinical value as they may
enable higher dosages without calcium toxicity.
The basis of the antilymphoma effect is uncertain. A prob-
lem in studying the biology of low grade lymphoma is the
lack of suitable in vitro and in vivo models. Low grade
lymphoma cells do not proliferate in vitro without adultera-
tion for example by immortalisation with the Epstein Barr
virus or culture with CD4+ cells (Umetsu et al., 1990) and
such interventions clearly will change the nature of the cells
studied. An in vitro model which may represent some aspects
of follicular lymphoma cell biology are those cell lines which
have a t(14;18) chromosomal translocation since this abnor-
mality is found in at least 85% of cases of follicular NHL in
association with rearrangement of the bcl2 gene (Yunis et al.,
1987; Weiss et al., 1987).
The aim of this study was to investigate the antiproli-
ferative effect and the induction of differentiation of vitamin
D3 on t(14;18) lymphoma cell lines and relate this to expres-
sion of the VDR in lymphoma tumour biopsy material.
1,25(OH)2D3 and an analogue, MC903 (calcipotriol) which
has equivalent VDR binding affinity but 100 fold less effect
on Ca2+ metabolism were assayed.
Materials and methods
Cells
The cell lines studied for their response to 1,25(OH)2D3 and
MC903 were as follows: SU-DHL4 and SU-DUL5 (both
derived from high grade B cell lymphoms): each carries a
t(14;18) with an associated rearrangement of the bc12 gene; in
SU-DHL4 rearrangement through the major breakpoint
region (Cleary et al., 1986a) and SU-DUL5 rearrangement
through the minor cluster region (Cleary et al., 1986b). U937
is a monoblastic cell line for which both 1,25(OH)2D3 and
MC903 have been shown to inhibit proliferation and pro-
mote differentiation along the monocytic/macrophage path-
way. SU-DHL4 cells were a gift from Dr A. Epstein (UCLA,
Los Angeles, CA), SU-DUL5 cells were a gift from Dr M.
Cleary (Stanford, CA). Cells were cultured in medium sup-
plemented with 10% foetal bovine serum in humidified
atmosphere with 5% C02.
1,25(OH)2D3 and MC903
1,25(OH)2D3 and MC903 (provided by Dr L. Binderup, Leo
Laboratories, Denmark) were dissolved in 100% ethanol to
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a stock concentration of 10-3 M and stored at - 20°C and
protected from light. Dilutions of the stock solutions were
made in ethanol and then medium. The maximum concentra-
tion of ethanol in culture (0.1%) did not influence cell
growth.
Modulation ofcellproliferation and analysis ofdifferentiation
Cells in log phase growth were seeded at 2 x I0O cell ml-'
and either agent (or vehicle = control) were added at the
required concentration. Cells were counted daily using a
Coulter counter and assayed for viability with Trypan blue.
Each experiment lasted 5 days. On days 0 and 4 cells were
examined using a panel of monoclonal antibodies to assay
for differentiation. The experiment was performed in dup-
licate and repeated once.
J,25(OH)2D3 receptor binding assay
Cells were harvested by centrifugation and washed twice in
ice cold phosphate buffered saline. Cells were then homo-
genised in KTMED (KC12 22.4gV1', Tris Cl 1.21 g1V',
sodium molybate 2.06 g 1'-l, EDTA 0.336 g 1- , Dithiothreitol
0.62 g 1-' lI07 cells ml-' were sonicated and then centrifuged
l00,000g for 1 h. One hundred and ninetyjil of cytosol is
then added to 10ftl [3H]-1,25(OH)2D3 (2.6 x 10-8 M) either
with or without excess radioinert 1,25(OH)2D3. After 4 h
incubation receptor-bound [3]-1,25(OH)2D3 was separated
from free [3H]-1,25(OH)2D3 with hydroxylapatite (Colston et
al., 1980). Cytosol protein concentration was determined by
the method of Bradford (Bradford, 1976). The experiment
was performed in duplicate and repeated once.
Tumour samples and assayfor VDR expression
Tumour biopsy specimens were snap frozen and 5 ytm cryo-
stat sections were mounted onto poly-l-lysine coated slides
and fixed in 4% formaldehyde and methanol and washed in
phosphate buffered saline. (Fixed sections were stored at
- 20°C in glycerol/sucrose storage medium before staining.)
Sections were analysed for the presence of the VDR using a
Vectastain ABC anti-rat alkaline phosphatase kit with the
monoclonal antibody 9A7a (provided by Dr J. Wesley Pike).
The alkaline phosphatase substrate contained a levamisole
block. Sections were processed in duplicate. The MCF-7 cell
line which has a high level of VDR expression served as the
positive control.
Results
Effect of1,25(OH)2D3 and MC903 on cellproliferation
These agents inhibited the proliferation of SU-DHL4 and
SU-DUL5 with no effect on cell viability (Figure 1) at
10-7 M. There was no effect on proliferation at lower concen-
trations. U937 was inhibited at lower concentrations of each
as recorded elsewhere (Binderup & Bramm, 1988). At 10-7 M
there was an approximately 50% reduction of proliferation
of SU-DHL4 and SU-DUL5 on day 4.
Effect of1,25(OH)2D3 and MC903 on induction of
differentation (Table I)
SU-DHL4 acquired markers of mature B-cell differentiation
(Bi, B4 and CD38) whilst SU-DUL5 lost a marker of
immaturity (CD14) when cultured with each agent at I0-7 M.
U937 has been demonstrated to differentiate along the
monocyte/macrophage pathway when cultured in the pre-
sence of 1,25(OH)2D3 and MC903 (Dodd et al., 1983;
Binderup & Bramm, 1988; Bhalla et al., 1989) and this was
confirmed in these experiments.
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Figure 1 Growth curves (means ± s.e.m.) for the SU-DHL4 and
SU-DUL5 cell tines after culture in the presence of vehicle (con-
trol), 1,25(OH)2D3 and MC903 each at a concentration of
I0-7 M. Cell viability was unaffected. There was no effect of
either agent at lower concentrations (10-8 to 10-9M, data not
shown).
Table I Effect of 1,25(OH)2D3 and MC903 on induction of
differentiation
Immunocytochemistry profile VDR level (fmolmg-')
SU-DHL4 T=O =96h
Controls No change 12.0 12.3 NS
MC903 + B1, + B4, + CD38 12.0 12.3 NS
1,25(OH)2D3 4 B1, 4 B4, 4 CD38 12.0 9.7 P<0.001
SU-DUL5
Controls No change 10.4 9.9 NS
MC903 4, CD14 10.4 9.6 NS
1,25(OH)2D3 + CD14 10.4 12.7 P<0.05
U937
Controls No change 97.5 95.7 NS
MC903 4'CD14 115.5 113.0 NS
1,25(OH)2D3 4 CD14 94.6 112.0 NS
(1,25(OH)2D3, MC903 at 10-7 M)
Effect of1,25(OH)2D3 and MC903 and VDR expression
(competitive binding assay) (Table I)
Expression of VDR was low in SU-DHL4 and SU-DUL5
both before and after treatment with each agent over 5 days
at 10-7 M in comparison to the U937 cell line. One way
analysis of variance was applied to the data. Dunnet's test
(Zar, J.H.) demonstrated that incubation with 1,25(OH)2D3
over 96h produced a reduction in VDR expression in the
SU-DHL4 cells (P<0.001, 2 tailed test) and an increase in
VDR expression in the SU-DUL5 cells (P<0.05, 2 tailed).
MC903 had no effect on VDR expression in either cell line.670 T. HICKISH et al.
a
Neither agent significantly altered expression of the VDR at
96 h in the U937 cell line.
VDR expression; immunocytochemistry oflymph node biopsy
specimens
Results are summarised in Table II (and see Figure 2).
Biopsy samples were analysed for VDR expression from 13
patients with various categories of NHL as defined by the
Working Formulation. VDR expression was detectable in
11/13 samples. Only in a case of high grade lymphoblastic-
lymphoma was there strong staining comparable to the
MCF-7 cell line. In the two negative cases, the macrophages
stained positively providing an internal positive control. In
all cases macrophages stained strongly positive as did cells in
the paracortex which by morphology and location were con-
sidered to be T cells.
Figure 2 Immunostaining with 9A7a for the VDR. a, The
MCF7 cell line - expresses the VDR abundantly. b, A lymph
node biopsy from a case of follicular mixed small cleaved and
large cell lymphoma (working formulation category C). Note
weak positive staining and occasional intensely staining cells
which in the section shown are macrophages. c, A lymph node
biopsy from a case of lymphoblastic lymphoma. The tumour cells
are strongly positive.
Table II Intensity of staining for the VDR in relation to histological
classification according to the working formulation
Patient Histology Intensity ofstaining
M.B. WF: B Weak +ve
L.S. C Not detected
M.L. C Not detected
T.F. C Weak +ve
G.H. C Weak +ve
K.K. C Weak +ve
J.P. G Weak +ve
A.M. Tranformed F
to H Weak +ve
R.M. G Moderate +ve
J.J. H Weak +ve
M.G. Richters Weak +ve
J.L. J Strong +ve
M.S. J Moderate +ve
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Discussion
1,25(OH)2D3 and its analogue, MC903, had an equivalent
antiproliferative effect on the SU-DHL4 and SU-DUL5 cell
lines and this was associated with the induction of
differentiation. The expression of the VDR was low in both
cell lines in accord with other studies (Kizaki et al., 1991)
but was slightly altered (± 20%) by incubation with
1,25(OH)2D3 and not MC903 over 96 h. The reason for the
apparent discrepancy between the two drugs in impact on
VDR expression, particularly as they had a similar effect on
proliferation, is unclear. The time-course of VDR modula-
tion in response to each drug may differ and hence the
response to MC903 may have been missed. The observation
that 1,25(OH)2D3 produced a reduction in VDR expression
in SU-DHL4 and an increase in SU-DUL5 on day 4 may
also reflect different time-course functions of VDR modula-
tion in each cell line.
However these effects occurred at a relatively high con-
centration (10- M) of 1,25(OH)2D3 which exceeds the
physiological concentration by approximately 103-104 fold.
Furthermore expression of VDR in the follicular NHL
tumour samples was low. These data suggest th.t nike
observed clinical response of advanced follicuiar NHL to
1,25(OH)2D3 may not be due to a c'irect action of the agent
on the lymphoma cells. CD4+T helper cells which recognise
alloantigens expressed by follicular lymphoma cells induce
the lymphoma cells to proliferate (Umetsu et al., 1990)
indicating a possible role for CD4+T cells in promoting
follicular NHL. 1,25(OH)2D3 inhibits CD4+T cell prolifera-
tion over a concentration range I0-'-10-1 M and this effect
on CD4+T cells appears to be both direct and also indirect
through suppression of ILl production by monocytes
(Jordan et al., 1990; Tsoukas et al., 1989; Rigby, 1988;
Binderup, 1992). Therefore the antifollicular NHL effect of
1,25(OH)2D3 may be mediated (at least in part) by an
inhibitory effect on CD4+T cells. The development of the
bcl2 transgenic mouse (McDonnell et al., 1989) provides a
novel model of follicular NHL and may enable an in vivo
analysis of the interplay between B and T cells under the
influence of 1,25(OH)2D3 and its analogues. Certainly the
t(14;18) cell lines are limited as a model of follicular NHL
since they are derived from high grade B cell lymphomas.
Nevertheless, if the antiproliferative and differentiation-
promoting effect produced by 1,25(OH)2D3 on the SU-DHL4
and SU-DUL5 cell lines extends to lymphoma of follicle
centre cell type, then using 1,25(OH)2D3 analogues it may be
possible to achieve serum levels that act directly on the
centrocytes, in addition to the postulated indirect mechanism
of T cell inhibition, without perturbing calcium metabolism.
This work was supported in part by the Cancer Research Campaign.
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